Iterum Therapeutics plc (NASDAQ: ITRM) has announced the conclusion of a late-cycle meeting with the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for sulopenem etzadroxil/probenecid. The drug is under review for the treatment of uncomplicated urinary tract infections (uUTIs) in patients with quinolone non-susceptible pathogens.
The FDA has communicated that an Antimicrobial Drugs Advisory Committee meeting is not currently required and is working towards the scheduled action date of July 25. During the meeting, the FDA shared ongoing review issues, to which Iterum Therapeutics provided responses. This interaction is a crucial step toward potential approval.
In April, Iterum Therapeutics disclosed that the FDA required additional time to review the sulopenem application, leading to the postponement of the FDA Antimicrobial Drugs Advisory Committee meeting initially scheduled for June 2. The recent late-cycle meeting and the FDA's decision to proceed without an advisory committee suggest that the review process is advancing positively.
Sulopenem, if approved, would offer a new treatment option for uUTIs, particularly those resistant to quinolone antibiotics. The increasing prevalence of antibiotic-resistant bacteria necessitates the development of new antimicrobial agents to combat infections effectively. The successful review and potential approval of sulopenem could address a significant unmet medical need in treating uUTIs.
